GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Brokerages

GeoVax Labs, Inc. (NASDAQ:GOVX) has been given an average recommendation of “Buy” by the seven research firms that are currently covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $14.20.

GOVX has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a research report on Friday, November 15th. Alliance Global Partners started coverage on shares of GeoVax Labs in a report on Monday, November 11th. They issued a “buy” rating and a $15.00 price target on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $18.00 price objective on shares of GeoVax Labs in a research note on Tuesday, November 19th. Finally, Noble Financial increased their target price on shares of GeoVax Labs from $6.00 to $10.00 and gave the stock an “outperform” rating in a research note on Monday, August 19th.

GeoVax Labs Stock Down 2.7 %

NASDAQ GOVX opened at $2.19 on Friday. GeoVax Labs has a 52 week low of $1.09 and a 52 week high of $11.18. The firm’s 50-day simple moving average is $2.31 and its two-hundred day simple moving average is $2.70.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.91) EPS for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.38. The business had revenue of $2.79 million for the quarter, compared to analysts’ expectations of $1.84 million. During the same quarter in the previous year, the company posted ($4.80) earnings per share. As a group, research analysts forecast that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Institutional Trading of GeoVax Labs

A hedge fund recently bought a new stake in GeoVax Labs stock. Virtu Financial LLC acquired a new stake in GeoVax Labs, Inc. (NASDAQ:GOVX) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned approximately 0.43% of GeoVax Labs as of its most recent filing with the SEC. Hedge funds and other institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.